SCHEDULE 13G/A: FMR LLC and Abigail Johnson Disclose 10.2% Stake in Veracyte Inc.
Beneficial Ownership Disclosure
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 10.2% of Veracyte Inc.'s common stock as of April 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson, as reporting persons, have filed an Amendment No. 1 to Schedule 13G concerning their beneficial ownership of Veracyte Inc. common stock.
- As of April 30, 2025, FMR LLC and Abigail P. Johnson collectively beneficially own 7,922,821.66 shares of Veracyte Inc. common stock.
- This aggregate amount represents 10.2% of the total outstanding common stock of Veracyte Inc.
- FMR LLC holds sole voting power over 7,915,916.00 shares and sole dispositive power over 7,922,821.66 shares.
- Abigail P. Johnson's beneficial ownership is derived from her role as Director, Chairman, and CEO of FMR LLC, and the Johnson family's controlling interest in FMR LLC.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Veracyte Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, indicating a neutral sentiment. It neither presents positive nor negative operational or financial news for the issuer.
Positives
- Significant institutional investment from FMR LLC, a major asset manager, indicates confidence in Veracyte Inc.
- The filing explicitly states that the shares were acquired and are held in the ordinary course of business, not for control purposes, which suggests a passive investment stance.
Negatives
- No explicit negatives are present in this type of filing, as it is primarily a disclosure of ownership rather than a performance report.
Risks
- No specific risks related to Veracyte Inc.'s operations or financial health are disclosed in this ownership filing.
- The filing does not indicate any intent to influence or change control of the issuer, mitigating a potential risk of activist investor engagement from this party.
Future Outlook
NA
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."
Industry Context
This filing indicates a significant passive investment by a major asset management firm, FMR LLC (Fidelity), in Veracyte Inc., a company operating in the healthcare diagnostics sector. Such disclosures are routine for institutional investors crossing certain ownership thresholds and provide transparency into large holdings within public companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure Clarification | The filing details the internal governance of FMR LLC, noting that Abigail P. Johnson is a Director, Chairman, and CEO, and that the Johnson family, through their ownership of Series B voting common shares and a shareholders' voting agreement, may be deemed to form a controlling group with respect to FMR LLC. This structure dictates how FMR LLC's beneficial ownership is reported. | NA | Clarifies the ultimate control and reporting structure of the beneficial owner, FMR LLC, and its relationship with Abigail P. Johnson. |
Related Party Transactions
- The filing highlights the relationship between FMR LLC and Abigail P. Johnson, where Abigail P. Johnson's beneficial ownership is derived from her leadership role and the Johnson family's controlling interest in FMR LLC. This clarifies the reporting structure for a significant beneficial owner and a related entity.
Stakeholder Impact
- Shareholders: The disclosure of a significant 10.2% stake by a prominent institutional investor like FMR LLC can be viewed positively, signaling institutional confidence in Veracyte Inc. It also provides transparency regarding major shareholders.
- Management: The filing explicitly states that the shares are not held for the purpose of changing or influencing control, which may reassure Veracyte Inc.'s current management regarding potential activist pressure from this specific investor.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of FMR LLC. |
| 01/10/2023 | Date of Schedule 13G filing by FMR LLC where the Power of Attorney (accession number -23-000003) was incorporated by reference. |
| 01/26/2023 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of Abigail P. Johnson. |
| 01/31/2023 | Date of Schedule 13G filing by FMR LLC where the Power of Attorney (accession number -23-000038) for Abigail P. Johnson was incorporated by reference. |
| 04/30/2025 | Date of event which requires filing of this statement (measurement date for beneficial ownership). |
| 05/06/2025 | Date of signing and filing of the Schedule 13G Amendment No. 1. |
Keywords
Veracyte Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.